Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression

• Status: Unknown status
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

60 patients with chronic major depressive disorder according to DSM-IV will be included into the study. Patients will be randomized to receive an open treatment either with CBASP, a psychotherapy for chronic depression, or pharmacological treatment with Escitalopram for 28 weeks.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Freiburg
• Collaborator: University Hospital, Bonn
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Chronic MDD according to DSM-IV (modification: depressive symptomatology for at least one year), or recurrent MDE (third or greater episode with the immediately preceding episode being no more than 2.5 years before the onset of the present episode)

• Age 18-65

• Score of at least 18 on the Montgomery-Asberg-Rating Scale for Depression (MADRS)

Exclusion Criteria:

• Acute risk for suicide

• History of psychotic symptoms, bipolar disorder or dementia

• Severe substance-related abuse or dependence disorder

• Schizotypal, antisocial or borderline personality disorder

• Serious medical condition

• Severe cognitive impairment

• Absence of a response to previous adequate trial of the study medication/CBASP

• Hypersensitivity to Escitalopram

• Treatment with a MAO-inhibitor within 1 week before the initiation of study treatment